ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
109.87
-2.03 (-1.81%)
At close: Apr 28, 2026, 4:00 PM EDT
110.18
+0.31 (0.28%)
After-hours: Apr 28, 2026, 6:49 PM EDT
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 69 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
69
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$77,764
Profits / Employee
-$5,719,201
Market Cap
8.86B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 69 | 0 | - | 69 | 0 |
| Dec 31, 2024 | 69 | 8 | 13.11% | 69 | 0 |
| Dec 31, 2023 | 61 | 37 | 154.17% | 61 | 0 |
| Dec 31, 2022 | 24 | 0 | - | 24 | 0 |
| Dec 31, 2021 | 24 | -3 | -11.11% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
ABVX News
- 6 days ago - Abivax to Present Data on Obefazimod at Digestive Disease Week® - GlobeNewsWire
- 8 days ago - Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents - GlobeNewsWire
- 21 days ago - This Beaten-Down Drug Stock Is Down Over 10% -- Is It Finally a Buy? - The Motley Fool
- 27 days ago - Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies - GlobeNewsWire
- 4 weeks ago - 2 Healthcare Stocks That Could Soar Over the Next 5 Years - The Motley Fool
- 5 weeks ago - Abivax CEO Downplays Sale Talk, Eyes Capital Raise As Key Trial Data Readout Nears - Benzinga
- 5 weeks ago - Abivax in no rush for a deal, confident key June trial data can secure better terms for partnerships, CEO tells CNBC - CNBC
- 5 weeks ago - 2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool